ArticleDiscover oncology2025
Flavonoid GL-V9 suppresses development of human hepatocellular cancer cells by inhibiting Wnt/β-Cantenin signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Distant metastasis and post-operative recurrence of tumours are the main causes of death in patients with hepatocellular carcinoma (HCC). In recent years, flavonoids have been found to achieve effective anticancer effects by inhibiting cancer cell proliferation and inducing apoptosis, inhibiting cancer cell invasion and metastasis and neovascularization. GL-V9 is a newly synthesized flavonoid that has been demonstrated anticancer effects in a variety of tumors, but its anticancer effects in HCC and its related mechanisms are still unclear. In this study, we investigated the anti-proliferative, anti-invasive and anti-migratory activities of GL-V9 in HCC cells by MTT method cell proliferation assay, plate cloning assay, transwell invasion assay and cell scratching assay. Based on the results, we found that GL-V9 inhibits the EMT process through a pathway that inhibits Wnt/β-Cantenin pathway signaling, thereby reducing the proliferation, migration and invasion ability of HCC cells. Therefore, GL-V9 may be a novel potential therapeutic agent to inhibit HCC cell metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.